osr1 Antibody

What are the optimal methods for detecting OSR1 expression in tissue samples?

Immunohistochemistry (IHC) represents the gold standard for detecting OSR1 expression in paraffin-embedded tissue sections. For optimal results, the protocol should include:

• Standard deparaffinization and rehydration steps

• Hydrogen peroxide blocking

• Microwave-based antigen retrieval

• Overnight incubation with rabbit polyclonal antibody to OSR1 (1:50 dilution) at 4°C

• Staining with goat anti-rabbit IgG HRP (1:500)

• Visualization using diaminobenzidine solution

• Counterstaining with hematoxylin for 1 minute

For scoring, evaluate staining intensity (0-3) and extent of staining (0-4 based on percentage of immunoreactive tumor cells), with final scores of 0-6 indicating low expression and 8-12 indicating high expression .

How should OSR1 antibody specificity be validated for research applications?

Validation of OSR1 antibody specificity requires a multi-faceted approach:

• Western blot analysis comparing OSR1 expression in both normal and cancerous tissues to confirm single band detection at the expected molecular weight

• Comparing expression patterns across multiple cell lines (such as HOSEpiCs, A2780, SKOV3, OVCAR3, and COC1) to establish baseline expression patterns

• Performing knockdown experiments using multiple siRNA sequences (recommended sequences: 5'-GUGUCAAGAGUGUGGGAAATT-3', 5'-AGAAGGAAUUCGUCUGCAATT-3', and 5'-CCAGAAAAGAAGCCCACAATT-3') followed by antibody detection to confirm specificity

• Including positive and negative controls in all experiments, using overexpression vectors as positive controls and appropriate empty vectors as negative controls

What subcellular localization pattern should be expected when using OSR1 antibody?

OSR1 exhibits a specific subcellular localization pattern that should be observed when using a properly functioning antibody. Based on immunohistochemical analysis, OSR1 is primarily localized in the cytoplasm with partial localization in the nucleus . When validating a new OSR1 antibody, researchers should confirm this characteristic distribution pattern. Aberrant localization patterns may indicate either antibody specificity issues or potentially interesting biological phenomena that warrant further investigation in the specific cellular context being studied.

How can OSR1 antibody be applied to investigate the relationship between OSR1 and the NF-κB pathway?

To investigate OSR1's regulatory effect on the NF-κB pathway, researchers should implement a comprehensive experimental design:

• Establish OSR1 knockdown and overexpression cell models

• Perform Western blot analysis to examine key NF-κB pathway components (p-IκBα, IκBα, p65, and p-p65) in both models

• Use the OSR1 antibody in co-immunoprecipitation experiments to identify direct protein interactions

• Implement dual inhibition experiments using OSR1 knockdown combined with NF-κB pathway inhibitors (such as BAY 11-7082 at 20 μM concentration)

• Evaluate downstream effects through functional assays (proliferation, apoptosis, invasion, migration)

• Quantify NF-κB target genes expression through qRT-PCR and ELISA

Recent research has demonstrated that OSR1 knockdown activates the NF-κB pathway, while OSR1 overexpression suppresses it, suggesting OSR1 exerts its tumor-suppressive effects at least partially through NF-κB pathway inhibition .

What are the most effective protocols for analyzing OSR1's impact on cancer cell phenotypes using OSR1 antibody?

To comprehensively analyze OSR1's impact on cancer cell phenotypes, implement the following methodological framework:

Proliferation Assessment:

• CCK-8 assay: Seed 3×10³ cells per well in 96-well plates with measurements at 12, 24, 36, and 48h

• Cell cycle analysis: Fix 5×10⁵ cells with 70% cold ethanol for 12h at 4°C, stain with PI solution containing RNase A, and analyze by flow cytometry

• Western blot using OSR1 antibody alongside proliferation markers (cyclin D1, PCNA)

Migration and Invasion Analysis:

• Wound healing assay: Create wounds using 200-μL pipette tip in mitomycin C (20 μg/mL) treated cells

• Transwell invasion assay: Assess invasion capacity through Matrigel-coated membranes

• ELISA for quantifying MMP-2 and MMP-9 levels

Apoptosis Evaluation:

• Annexin V-FITC/PI flow cytometry

• Hoechst staining assay

• Western blot analysis of apoptosis-related proteins (Bcl-2, Bax, Cleaved Caspase-3)

How can researchers address potential inconsistencies between OSR1 antibody signal and clinical outcomes?

When addressing inconsistencies between OSR1 antibody signals and clinical outcomes, researchers should implement this systematic approach:

• Stratify patient samples by multiple clinical parameters beyond OSR1 expression alone (FIGO stage, differentiation, lymph node metastasis)

• Perform multivariate Cox regression analysis to identify independent prognostic factors

• Consider technical variables such as antibody batch, fixation time, and staining protocols

• Evaluate OSR1 in combination with other biomarkers for improved prognostic value

• Investigate potential post-translational modifications that might affect antibody recognition but not biological function

The table below summarizes Cox regression analysis findings on OSR1 and clinical outcomes:

What methodological considerations are crucial when using OSR1 antibody to study epigenetic regulation of OSR1 expression?

When investigating epigenetic regulation of OSR1 expression using OSR1 antibody, researchers should consider these critical methodological approaches:

• Examine promoter methylation status using bisulfite sequencing or methylation-specific PCR

• Implement chromatin immunoprecipitation (ChIP) assays to identify transcription factors and histone modifications at the OSR1 promoter

• Treat cells with epigenetic modifiers (DNA methyltransferase inhibitors like 5-aza-2'-deoxycytidine or histone deacetylase inhibitors) and monitor OSR1 expression changes via Western blot

• Combine OSR1 antibody with antibodies against histone marks (H3K4me3, H3K27me3) in sequential ChIP experiments

• Correlate methylation patterns with OSR1 protein expression in clinical samples

Previous research has demonstrated that OSR1 downregulation in gastric cancer and lung carcinoma occurs through promoter CpG methylation . Similar epigenetic mechanisms may explain OSR1 downregulation in ovarian cancer, though this requires further investigation. Researchers should ensure proper controls when studying these mechanisms, including cell lines with known OSR1 methylation status.

What are common challenges in OSR1 antibody-based immunohistochemistry and how can they be addressed?

Common challenges in OSR1 antibody-based IHC include:

Background Staining Issues:

• Problem: Non-specific binding leading to high background

• Solution: Optimize blocking conditions (increase blocking time to 2 hours, use 5% BSA instead of standard blocking reagents), implement additional washing steps, and titrate primary antibody concentration (start with 1:50 dilution and optimize as needed)

Weak or Absent Signal:

• Problem: Insufficient antigen retrieval or antibody concentration

• Solution: Test multiple antigen retrieval methods (citrate buffer pH 6.0 vs. EDTA buffer pH 9.0), extend antibody incubation time to overnight at 4°C, and validate antibody reactivity with positive control samples

Inconsistent Staining Patterns:

• Problem: Variable fixation times affecting epitope accessibility

• Solution: Standardize tissue processing protocols, maintain consistent fixation times (24h recommended), and consider using tissue microarrays for comparative studies

Scoring Variability:

• Problem: Subjective assessment affecting reproducibility

• Solution: Implement dual independent pathologist scoring, utilize digital image analysis software, and employ the established scoring system (intensity 0-3, extent 0-4) as described in the methodology

How should researchers interpret contradictory results between OSR1 mRNA and protein levels?

When confronted with discrepancies between OSR1 mRNA and protein levels, researchers should:

• Verify antibody specificity using multiple antibodies targeting different OSR1 epitopes

• Investigate post-transcriptional regulatory mechanisms:

  • Examine microRNA regulation through predictive algorithms and validation experiments

  • Assess protein stability using cycloheximide chase assays

  • Evaluate ubiquitination status through immunoprecipitation with OSR1 antibody followed by ubiquitin blotting

• Consider technical variables:

  • RNA quality and extraction methods

  • Protein extraction protocols (particularly important for nuclear proteins)

  • Normalization methods for both qRT-PCR and Western blot

• Implement time-course experiments to detect potential temporal disconnections between transcription and translation

Discrepancies between mRNA and protein levels often reveal important biological mechanisms that may be therapeutically targetable, such as miRNA-mediated suppression or enhanced protein degradation pathways.

What controls are essential when using OSR1 antibody in research investigating OSR1 as a potential therapeutic target?

When using OSR1 antibody to investigate its potential as a therapeutic target, these controls are essential:

Positive Controls:

• Cell lines with confirmed high OSR1 expression (based on literature, HOSEpiCs show higher expression than ovarian cancer cell lines)

• OSR1 overexpression systems using verified expression vectors (pcDNA3.1(+) vector containing OSR1 coding sequences)

• Normal ovarian tissue sections (showing 75% high expression rate)

Negative Controls:

• Cell lines with confirmed low OSR1 expression (A2780, SKOV3, OVCAR3, and COC1 show reduced expression)

• OSR1 knockdown using validated siRNA sequences

• Empty vector transfections for overexpression experiments

• Isotype controls for immunostaining experiments

• Secondary antibody-only controls

Functional Validation Controls:

• Dual inhibition experiments (OSR1 knockdown + NF-κB pathway inhibitor) to confirm specificity of observed effects

• Rescue experiments restoring OSR1 expression in knockdown models

• Dose-response evaluations when testing potential therapeutic compounds targeting the OSR1 pathway

How can OSR1 antibody be utilized in developing novel therapeutic approaches for ovarian cancer?

OSR1 antibody can facilitate the development of novel therapeutic approaches through several strategic applications:

• Target Validation and Patient Stratification:

  • Use OSR1 antibody for immunohistochemical screening to identify patients with low OSR1 expression who might benefit from NF-κB pathway inhibitors

  • Correlate OSR1 expression with response to existing therapies to identify potential biomarker applications

• Drug Discovery Applications:

  • Implement high-throughput screening assays using OSR1 antibody to identify compounds that restore OSR1 expression

  • Develop cell-based reporter systems to monitor OSR1 activity in response to potential therapeutic agents

• Combination Therapy Development:

  • Use OSR1 antibody to monitor pathway modulation when combining NF-κB inhibitors (such as BAY 11-7082) with conventional chemotherapeutics

  • Investigate synergistic effects between epigenetic modifiers and NF-κB pathway inhibitors on OSR1 expression and function

• Therapeutic Resistance Mechanisms:

  • Apply OSR1 antibody to investigate changes in OSR1 expression during acquired resistance to conventional therapies

  • Explore compensatory signaling pathways activated in response to OSR1 restoration

What methodological approaches can enhance the sensitivity and specificity of OSR1 detection in liquid biopsies?

To enhance OSR1 detection in liquid biopsies, researchers should consider these methodological approaches:

• Optimized Extraction Protocols:

  • Implement differential centrifugation methods to isolate extracellular vesicles containing OSR1

  • Use precipitation-based concentration methods to enhance detection of low-abundance OSR1 protein

• Enhanced Detection Technologies:

  • Develop proximity extension assays (PEA) using OSR1 antibody pairs for improved sensitivity

  • Implement digital ELISA platforms (e.g., Simoa) that can detect proteins at femtomolar concentrations

  • Design multiplex assays that simultaneously detect OSR1 alongside established ovarian cancer biomarkers (CA-125, HE4)

• Circulating Tumor Cell Analysis:

  • Combine OSR1 antibody with epithelial markers for CTC capture and characterization

  • Implement single-cell Western blot techniques for OSR1 detection in rare CTCs

• Quality Control Measures:

  • Establish standard operating procedures for pre-analytical sample handling

  • Include spike-in controls with recombinant OSR1 protein at known concentrations

  • Implement calibration curves using synthetic OSR1 peptides for absolute quantification

These approaches could potentially transform OSR1 from a tissue-based biomarker to a minimally invasive prognostic tool for monitoring ovarian cancer progression and treatment response.

How might emerging technologies enhance the research applications of OSR1 antibody beyond conventional methods?

Emerging technologies stand to revolutionize OSR1 antibody applications through these innovative approaches:

• Spatial Transcriptomics and Proteomics:

  • Combine OSR1 antibody staining with spatial transcriptomics to correlate protein expression with the surrounding tissue microenvironment

  • Implement imaging mass cytometry to simultaneously assess multiple proteins alongside OSR1 in the same tissue section

• Advanced Microscopy Techniques:

  • Apply super-resolution microscopy to investigate OSR1's precise subcellular localization

  • Implement live-cell imaging using fluorescently tagged OSR1 antibody fragments to track dynamic changes in OSR1 localization

• Antibody Engineering:

  • Develop recombinant nanobodies against OSR1 for improved tissue penetration

  • Create bispecific antibodies targeting OSR1 and NF-κB pathway components for therapeutic applications

• Artificial Intelligence Applications:

  • Implement machine learning algorithms to analyze OSR1 staining patterns and correlate with patient outcomes

  • Develop predictive models integrating OSR1 expression with other molecular markers to enhance prognostic accuracy

• In Situ Sequencing:

  • Combine OSR1 antibody detection with in situ RNA sequencing to correlate protein expression with transcriptional profiles at the single-cell level

  • Implement multiplexed error-robust FISH (MERFISH) alongside OSR1 antibody staining to create comprehensive spatial maps of pathway regulation

These emerging technologies promise to elevate OSR1 research beyond conventional applications, potentially revealing new biological insights and therapeutic opportunities for ovarian cancer patients.